Free Trial

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

-0.16 (-0.95%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
6.58 million shs
Average Volume
10.95 million shs
Market Capitalization
$18.61 billion
P/E Ratio
Dividend Yield
Price Target

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
11.1% Downside
$14.75 Price Target
Short Interest
1.09% of Shares Sold Short
Dividend Strength
News Sentiment
0.58mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
From $2.30 to $2.61 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.77 out of 5 stars

Medical Sector

845th out of 922 stocks

Pharmaceutical Preparations Industry

391st out of 423 stocks

TEVA stock logo

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

TEVA Stock News Headlines

These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction, and improved guidance pointing to additional upside.
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go (TEVA)
Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results.
Teva Says Simlandi Injection Now Available In U.S.
UBS Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.52 per share
Book Value
$6.73 per share


Outstanding Shares
Free Float
Market Cap
$18.61 billion
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

TEVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TEVA shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price target for 2024?

8 Wall Street analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $14.75 in the next year. This suggests that the stock has a possible downside of 11.1%.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA shares have increased by 59.0% and is now trading at $16.60.
View the best growth stocks for 2024 here

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our TEVA earnings forecast

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings results on Wednesday, November, 8th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The business had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.73 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive trailing twelve-month return on equity of 37.33%. Teva Pharmaceutical Industries's revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 EPS.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of 2.200-2.500 for the period, compared to the consensus earnings per share estimate of 2.410. The company issued revenue guidance of $15.7 billion-$16.3 billion, compared to the consensus revenue estimate of $15.9 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional investors include Maple Rock Capital Partners Inc. (0.39%), Swiss National Bank (0.30%), Capital International Investors (0.28%), Iron Triangle Partners LP (0.25%), Sumitomo Mitsui Trust Holdings Inc. (0.19%) and BNP Paribas Financial Markets (0.18%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Richard D Francis, Sven Dethlefs and Vikki L Conway.
View institutional ownership trends

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TEVA) was last updated on 5/27/2024 by Staff

From Our Partners